Monday, March 17, 2025 | 06:56 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covid-19 vaccine: I am not worried about the efficacy, says Jacob John

I would go for Bharat Biotech's Covaxin and not Covishield, and that is my personal judgment, the former head of Centre for Advanced Research in Virology at ICMR says

Jacob John
Premium

Jacob John, former head, Centre for Advanced Research in Virology, ICMR

Ruchika Chitravanshi
Emergency authorisation at a time when the pandemic is still raging has to prioritse safety of the vaccine, says Jacob John, former head of Centre for Advanced Research in Virology at the Indian Council of Medical Research (ICMR). While a controversy has broken out that the Bharat Biotech vaccine, Covaxin, has been given restricted use approval without efficacy data being available, John tells Ruchika Chitravanshi that given the circumstances, there were strong ethical considerations on both sides of the decision. Edited excerpts

What do you think of the approval given to Bharat Biotech’s vaccine?

The authorised regulator did not decide

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in